相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1972
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Eli Lilly has entered a definitive agreement to acquire Houston-based CrossBridge Bio for up to $300 million in cash to gain access to next-generation dual-payload antibody-drug conjugate technology. - CrossBridge Bio's lead candidate CBB-120 is a TROP2-targeting dual-payload ADC combining TOP1 and ATR inhibitors, designed to enhance therapeutic index and generate more durable responses than current TROP2-targeting ADCs. - The acquisition provides Lilly with innovative dual-payload ADC platform capabilities that could be transformative in oncology, with CBB-120's IND application anticipated in 2026. - CrossBridge Bio was founded in 2023 based on technology developed by Dr. Kyoji Tsuchikama at UTHealth Houston, representing the growing industry focus on advanced ADC approaches.
- A large observational study of 165,000 older adults found that high-dose influenza vaccines reduced Alzheimer's disease risk by nearly 55% compared to standard-dose vaccines over approximately two years. - The protective effect was more pronounced and lasted longer in women than men, with benefits observed up to 25-28 months after vaccination. - High-dose flu vaccines contain four times the antigen of standard vaccines and are already recommended by the CDC for adults 65 and older due to age-related immune system weakening. - Researchers hypothesize the protection may stem from enhanced immune responses that reduce systemic inflammation, which is thought to contribute to neurodegeneration and Alzheimer's development.
